SPOTLIGHT -
Lrvine, CA-ISTA Pharmaceuticals Inc. said its bromfenac sodium ophthalmic solution (Xibrom) once-daily formulation produced highly statistically significant results in its phase III clinical trials.
Visus Therapeutics completes enrollment in BRIO-I Phase 3 clinical trial of Brimochol PF for the treatment of presbyopia
The importance of ocular health prior to cataract and refractive surgery
Evidence-based debates and discussions at COPHy 2023
Commercial real estate and your practice, part two with Colin Carr
Genentech, American Diabetes Association partner to increase equitable access to eye health care
Study: New gene-editing technique reverses vision loss in mice